124 292

Cited 8 times in

The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation

DC FieldValueLanguage
dc.contributor.author김범석-
dc.contributor.author김유선-
dc.contributor.author박용정-
dc.contributor.author이재근-
dc.contributor.author이주한-
dc.contributor.author임범진-
dc.contributor.author정현주-
dc.contributor.author허규하-
dc.date.accessioned2016-02-04T11:53:08Z-
dc.date.available2016-02-04T11:53:08Z-
dc.date.issued2015-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/141416-
dc.description.abstractPURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when bortezomib was used to treat refractory AMR. MATERIALS AND METHODS: Eleven refractory AMR episodes treated with bortezomib were included in this study. The patients received one or two cycles of bortezomib (1.3 mg/m²) on days 1, 4, 8, and 11. RESULTS: Bortezomib effectively reduced antibodies against various targets, including human leukocyte antigen (HLA) class I and II, ABO blood group antigen, and angiotensin II type 1 receptor. Antibodies were depleted or reduced significantly in eight AMR episodes. Overall, there was a significant improvement in the mean estimated glomerular filtration rate (eGFR) at 3 months after therapy (36.91±22.15 mL/min/1.73 m²) versus eGFR at time of AMR diagnosis (17.00±9.25 mL/min/1.73 m²; p=0.007). All six early-onset AMR episodes (within 6 months post-transplantation) showed full recovery of allograft function. Additionally, three of the five late-onset AMR episodes (>6 months post-transplantation) showed improved allograft function. CONCLUSION: Anti-humoral treatment based on bortezomib might be an effective strategy against refractory AMR caused by various types of antibodies. Notably, this treatment could be more effective in early-onset AMR than in late-onset AMR.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1638~1642-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAntibodies, Monoclonal/therapeutic use-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHBoronic Acids/therapeutic use-
dc.subject.MESHBortezomib/therapeutic use*-
dc.subject.MESHFemale-
dc.subject.MESHGraft Rejection/drug therapy*-
dc.subject.MESHGraft Rejection/prevention & control*-
dc.subject.MESHHumans-
dc.subject.MESHImmunoglobulins, Intravenous/therapeutic use-
dc.subject.MESHImmunologic Factors/therapeutic use-
dc.subject.MESHIsoantibodies-
dc.subject.MESHKidney Failure, Chronic/surgery*-
dc.subject.MESHKidney Transplantation*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPlasmapheresis-
dc.subject.MESHPyrazines/administration & dosage-
dc.subject.MESHTransplantation, Homologous-
dc.titleThe Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학)-
dc.contributor.googleauthorJuhan Lee-
dc.contributor.googleauthorBeom Seok Kim-
dc.contributor.googleauthorYongjung Park-
dc.contributor.googleauthorJae Geun Lee-
dc.contributor.googleauthorBeom Jin Lim-
dc.contributor.googleauthorHyeon Joo Jeong-
dc.contributor.googleauthorYu Seun Kim-
dc.contributor.googleauthorKyu Ha Huh-
dc.identifier.doi10.3349/ymj.2015.56.6.1638-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00488-
dc.contributor.localIdA00785-
dc.contributor.localIdA01582-
dc.contributor.localIdA03068-
dc.contributor.localIdA03163-
dc.contributor.localIdA03363-
dc.contributor.localIdA03771-
dc.contributor.localIdA04344-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid26446648-
dc.subject.keywordAngiotensin II type 1 receptor antibodies-
dc.subject.keywordHLA antibodies-
dc.subject.keywordantibody-mediated rejection-
dc.subject.keywordbortezomib-
dc.subject.keywordkidney transplantation-
dc.contributor.alternativeNameKim, Beom Seok-
dc.contributor.alternativeNameKim, Yu Seun-
dc.contributor.alternativeNamePark, Yong Jung-
dc.contributor.alternativeNameLee, Jae Geun-
dc.contributor.alternativeNameLee, Ju Han-
dc.contributor.alternativeNameLim, Beom Jin-
dc.contributor.alternativeNameJeong, Hyeon Joo-
dc.contributor.alternativeNameHuh, Kyu Ha-
dc.contributor.affiliatedAuthorKim, Beom Seok-
dc.contributor.affiliatedAuthorKim, Yu Seun-
dc.contributor.affiliatedAuthorPark, Yong Jung-
dc.contributor.affiliatedAuthorLee, Jae Geun-
dc.contributor.affiliatedAuthorLee, Ju Han-
dc.contributor.affiliatedAuthorLim, Beom Jin-
dc.contributor.affiliatedAuthorJeong, Hyeon Joo-
dc.contributor.affiliatedAuthorHuh, Kyu Ha-
dc.rights.accessRightsfree-
dc.citation.volume56-
dc.citation.number6-
dc.citation.startPage1638-
dc.citation.endPage1642-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.56(6) : 1638-1642, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.